Clinical Stage Pharma

Developing small molecules for the treatment of gastric acid related diseases.

About Cinclus Pharma
Cinclus Pharma

The Next Leap Forward

Blockbuster Proton Pump Inhibitors (PPIs) such as Losec and Nexium have not been able to provide all gastroesophageal reflux disease (GERD) patients with sufficient disease control. Time has now come for Potassium-Competitive Acid Blockers (P-CABs) to take the next leap forward in the treatment of acid related diseases. Cinclus Pharma’s clinical stage drug candidate linaprazan glurate, formerly known as X842, takes a new approach to provide improved management of GERD.

Learn more

Cinclus Pharma man with GERD startpage

Latest pressreleases


cinclus pharma illustration of linazapran molecule grey
Our lead asset

Linaprazan glurate

Built on world-leading industrial tradition, Linaprazan glurate is a gastric acid blocker and therapy with great potential for healing GERD. During 2021, clinical phase 1 trials were successfully completed and clinical phase II trials were initiated. Linaprazan glurate represents a new and novel mode of action with superior efficacy and pharmacokinetic profile versus PPI’s.

Learn more

Latest News


Cinclus Last Patient

Last Patient Out (LPO) from the Phase II study of linaprazan glurate

On September 1st, we had LPO – Last Patient Out, from the Phase II study of linaprazan glurate. The study includes a total of 228 patients.

Cinclus News Gosta

Gösta Hiller - A driven leader who wants to build smart teams and see people grow together

Gösta has extensive experience in leadership positions that will come in handy as Cinclus now prepares for the next step.

Cinclus News Peter

Peter Unge – Clinician and senior advisor with extensive experience in gastroenterology

Peter Unge's knowledge and long experience are essential assets in the clinical operations of Cinclus Pharma.

cinclus pharma bistro with greenery in the ceiling
Reflux diseases

AFFECTING SOCIAL LIFE AND WELLNESS

Most people can relate to discomfort caused by reflux and heartburn, two of the most common symptoms caused by GERD. Symptoms often occur during or after eating and drinking, which affects both motivation and the ability to enjoy social activities such as picnics, dinners, events or just a cup of coffee with friends. More severe stages of GERD can be very painful, with difficulty in swallowing and esophageal erosions or ulcerations (esophagitis).

Learn more about GERD

“We want to make a paradigm shift in the treatment of gastric acid related diseases. We will do this by registering, launching, and making our effective P-CAB linaprazan glurate available worldwide.”

Christer Ahlberg

CEO Cinclus Pharma